Treating head and neck cancer in the age of immunotherapy: a 2023 update

A Bhatia, B Burtness - Drugs, 2023 - Springer
Most patients diagnosed with head and neck squamous cell carcinoma (HNSCC) will
present with locally advanced disease, requiring multimodality therapy. While this approach …

Targeted therapy for head and neck cancer: signaling pathways and clinical studies

Q Li, Y Tie, A Alu, X Ma, H Shi - Signal transduction and targeted …, 2023 - nature.com
Head and neck cancer (HNC) is malignant, genetically complex and difficult to treat and is
the sixth most frequent cancer, with tobacco, alcohol and human papillomavirus being major …

Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)

Y Yang, J Pan, H Wang, Y Zhao, S Qu, N Chen, X Chen… - Cancer cell, 2023 - cell.com
Checkpoint inhibitors are effective in recurrent/metastatic nasopharyngeal cancer (R/M
NPC). RATIONALE-309 (NCT03924986) randomized 263 treatment-naive R/M NPC …

Phase I/Ib clinical trial of sabatolimab, an anti–TIM-3 antibody, alone and in combination with spartalizumab, an anti–PD-1 antibody, in advanced solid tumors

G Curigliano, H Gelderblom, N Mach, T Doi… - Clinical Cancer …, 2021 - aacrjournals.org
Abstract Purpose: Sabatolimab (MBG453) and spartalizumab are mAbs that bind T-cell
immunoglobulin domain and mucin domain-3 (TIM-3) and programmed death-1 (PD-1) …

Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma

YP Chen, JH Yin, WF Li, HJ Li, DP Chen, CJ Zhang… - Cell research, 2020 - nature.com
Nasopharyngeal carcinoma (NPC) is an aggressive malignancy with extremely skewed
ethnic and geographic distributions. Increasing evidence indicates that targeting the tumor …

Tumour heterogeneity and intercellular networks of nasopharyngeal carcinoma at single cell resolution

Y Liu, S He, XL Wang, W Peng, QY Chen… - Nature …, 2021 - nature.com
The heterogeneous nature of tumour microenvironment (TME) underlying diverse treatment
responses remains unclear in nasopharyngeal carcinoma (NPC). Here, we profile 176,447 …

Comprehensive single-cell sequencing reveals the stromal dynamics and tumor-specific characteristics in the microenvironment of nasopharyngeal carcinoma

L Gong, DLW Kwong, W Dai, P Wu, S Li, Q Yan… - Nature …, 2021 - nature.com
The tumor microenvironment (TME) of nasopharyngeal carcinoma (NPC) harbors a
heterogeneous and dynamic stromal population. A comprehensive understanding of this …

Nasopharyngeal carcinoma

YP Chen, ATC Chan, QT Le, P Blanchard, Y Sun, J Ma - The Lancet, 2019 - thelancet.com
Nasopharyngeal carcinoma is characterised by distinct geographical distribution and is
particularly prevalent in east and southeast Asia. Epidemiological trends in the past decade …

Single-cell and spatial transcriptome analyses reveal tertiary lymphoid structures linked to tumour progression and immunotherapy response in nasopharyngeal …

Y Liu, SY Ye, S He, DM Chi, XZ Wang, YF Wen… - Nature …, 2024 - nature.com
Tertiary lymphoid structures are immune cell aggregates linked with cancer outcomes, but
their interactions with tumour cell aggregates are unclear. Using nasopharyngeal carcinoma …

Single-cell transcriptomic analysis defines the interplay between tumor cells, viral infection, and the microenvironment in nasopharyngeal carcinoma

S **, R Li, MY Chen, C Yu, LQ Tang, YM Liu, JP Li… - Cell research, 2020 - nature.com
Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus (EBV)-associated malignancy
with a complex tumor ecosystem. How the interplay between tumor cells, EBV, and the …